% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • fezziwig2008 fezziwig2008 Apr 28, 2014 11:01 PM Flag

    Ph20 blocks repair of nerves in MS (blocks remyelination)

    Congressionally Directed Medical Research Programs

    Inhibition of PH20 Hyaluronidase May Effectively Promote Remyelination in Multiple Sclerosis Lesions

    Posted January 9, 2014
    Larry Sherman, Ph.D., Oregon Health & Science University, and Paul Weigel, Ph.D., Oklahoma Health Sciences Center

    In FY09, Dr. Sherman and Dr. Wiegel were awarded an MSRP Synergistic Idea Award, the intent of which is to support synergistic and multidisciplinary approaches to address a central critical problem or question in MS research. Dr. Sherman had already discovered that a high molecular form of hyaluronan (HA), one of the chief components of the extracellular matrix, accumulates in demyelinated lesions in MS patients, which led him to hypothesize that degrading the accumulated HAs via hyaluronidases (enzymes that break down HA) may promote remyelination.

    Unexpectedly, when the HAs were degraded in this fashion, the byproducts of some hyaluronidases prevented OPC maturation, leading Dr. Sherman to further hypothesize that specific hyaluronidases expressed in demyelinating lesions and their degradation products may be blocking OPC (Oligodendrocyte progenitor cells) maturation.
    HA digestion products formed by PH20, but not the others, inhibited OPC maturation and thus prevented remyelination, signifying PH20 as a promising molecular target for promoting remyelination in MS and other demyelinating diseases. Based on these findings, Drs. Sherman and Weigel aim to identify drugs that specifically inhibit PH20 hyaluronidase activity as a potential therapeutic for promoting remyelination in MS patients.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
7.43Feb 11 4:00 PMEST